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Minnesota, USAIntroduction: Alport syndrome (AS) is a genetic disorder characterized by progressive hematuric
nephropathy with or without sensorineural hearing loss and ocular lesions. Previous studies on AS
included mostly children.
Methods: To determine the prognostic value of loss of staining for collagen type IV alpha 5 (COL4A5) and
its relationship with the ultrastructural glomerular basement membrane alterations, we performed direct
immunoﬂuorescence using a mixture of ﬂuorescein isothiocyanate-conjugated and Texas-red conjugated
antibodies against COL4A5 and COL4A2, respectively, on renal biopsies of 25 males with AS (including 16
who were diagnosed in adulthood).
Results: All patients showed normal positive staining of glomerular basement membranes and tubular
basement membranes for COL4A2. Of the 25 patients, 10 (40%) patients showed loss of staining for
COL4A5 (including 89% of children and 13% of adults) and the remaining 15 (60%) had intact staining for
COL4A5. Compared with patients with intact staining for COL4A5, those with loss of staining had more
prominent ultrastructural glomerular basement membrane alterations and were younger at the time
of biopsy. By Kaplan-Meier survival analysis and Cox regression analysis, loss of staining for COL4A5
predicted earlier progression to overt proteinuria and stage 2 chronic kidney disease or worse. By
multivariate Cox regression analysis, loss of staining for COL4A5 was an independent predictor of the
development of overt proteinuria and stage 2 chronic kidney disease or worse.
Discussion: Thus, the COL4A5 expression pattern has an important prognostic value and it correlates with
the severity of ultrastructural glomerular basement membrane alterations in males with AS. Loss of
COL4A5 staining is uncommon in patients with AS diagnosed in their adulthood.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A lport syndrome (AS) (also known as Alport dis-ease or hereditary nephritis) is a genetic disorder
manifested by progressive hematuric nephropathy
with or without sensorineural hearing loss and ocular
lesions. The natural history of AS nephropathy is
characterized by persistent microhematuria followed,spondence: Samih H. Nasr, Division of Anatomic Pathology,
Clinic, Hilton 10-20, 200 First Street, SW, Rochester, Min-
a 55905, USA. E-mail: nasr.samih@mayo.edu
ved 4 September 2016; accepted 23 September 2016;
hed online 29 September 2016in the later stages of disease, by proteinuria and then
renal insufﬁciency. AS is due to mutations in one of the
collagen type IV (COL4) genes that disrupt the syn-
thesis of COL4 and/or the formation of COL4 protomers
and networks. Multiple modes of inheritance are
known. The X-linked type, which is due to mutations
in the gene encoding the a5 chain of COL4 (COL4A5)
present on chromosome X, is the most common. The
remaining cases are autosomal recessive or autosomal
dominant, and are due to mutations in the genes
encoding a3 (COL4A3) or a4 (COL4A4) chains that are
located on chromosome 2. De novo (sporadic) mutationsKidney International Reports (2017) 2, 44–52
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of renal disease. The median renal survival of males
with X-linked AS is 25 years, and 90% reach end-stage
renal disease (ESRD) by the age of 40.1 It has been
shown that the renal prognosis is dependent, to a
certain extent, on the underlying genetic defect, with
truncating mutations leading to more severe disease
and earlier progression to ESRD than missense muta-
tions.1,2 The development of proteinuria is a predictor
of progression to ESRD in AS.3
There are no speciﬁc histologic alterations of AS on
light microscopy. Early in the disease, glomeruli appear
unremarkable or show a mild increase in mesangial
matrix or mesangial cell number. Late in the disease, a
pattern of focal segmental glomerulosclerosis may
develop, associated with a variable degree of tubular
atrophy and interstitial ﬁbrosis (TA/IF). Interstitial
foam cells are commonly identiﬁed, even before the
development of heavy proteinuria. The diagnostic
histologic ﬁnding in AS is seen on the ultrastructural
examination of glomeruli. There are thickening,
lamellation, and reticulation of the glomerular base-
ment membranes (GBM), imparting a characteristic
“basket-weave” appearance.4 Scalloping of the outer
aspect of the GBM and electron-dense microgranules,
20 to 60 nm in diameter, are frequently seen in the
lucent areas between the GBM lamellations. These ul-
trastructural ﬁndings can be focal and segmental, and
the unaffected segments may show GBM thinning. In
some cases, especially in young boys and female het-
erozygotes with X-linked disease, the only ultrastruc-
tural ﬁnding may be diffuse thinning of the GBM.
Because of the large size of the COL4 genes and the
numerous disease-causing mutations identiﬁed so far
(1900 variants in COL4A5 alone),5 staining for COL4
chains has become a useful adjunct to establish the
diagnosis and determine the mode of inheritance.6–8
COL4 is composed of 6 chains, a1–a6, coiled around
each other to form triple helical protomers, of which only
3 conﬁgurations have been discovered, a1.a1.a2.(IV),
a3.a4.a5.(IV), and a5.a5.a6.(IV).9 The triple helical
protomers form hexamers, of which only 3 pairings
exist: a1.a1.a2.(IV)–a1.a1.a2.(IV), a3.a4.a5.(IV)–a3.a4.
a5.(IV), and a1.a1.a2.(IV)–a5.a5.a6.(IV).9 The a1.a1.
a2.(IV)–a1.a1.a2.(IV) network is expressed in GBM,
mesangial matrix, Bowman’s capsule (BC), and tubular
basement membranes (TBM). The a3.a4.a5.(IV)–a3.a4.
a5.(IV) network is expressed in mature GBM, BC, and
distal TBM. The a1.a1.a2.(IV)–a5.a5.a6.(IV) network is
expressed in BC and distal TBM. In X-linked AS, typi-
cally there is loss of COL4A5 staining of GBM, BC, and
distal TBM, whereas in autosomal AS, there is loss of
COL4A5 staining of GBM with intact staining of BC andKidney International Reports (2017) 2, 44–52distal TBM.6,7,10 In contrast, patients with thin basement
membrane nephropathy typically have intact GBM
staining for COL4 subunits,11 with the caveat that female
carriers of AS often have thin GBM lesions and may
show mosaic loss of staining.
Many previous studies have addressed the pathol-
ogy, genetics, and treatment of AS; however, only a
few, which included mostly children, have evaluated
the prognostic value of COL4 chain staining12,13 and
the relationship between COL4 chain expression and
ultrastructural GBM alterations.8,14 In this study, we
aim to address the following 3 questions: (1) Does loss
of glomerular staining for COL4A5 have a prognostic
value? (2) Does it correlate with the ultrastructural
GBM alterations? and (3) Does staining for COL4A5
help in conﬁrming the diagnosis of AS in cases that
show only mild ultrastructural GBM alterations?
MATERIALS AND METHODS
We reviewed the renal pathology archives at the Mayo
Clinic, from 2007 to 2015, and identiﬁed 28 males with AS
who had fulﬁlled all of the following 3 criteria: (1) clin-
icopathologic diagnosis of AS including the presence of
the deﬁning ultrastructural ﬁnding of GBM basket weave
change; (2) family history of hematuria (with or without
renal failure) and/or hearing loss; and (3) adequate re-
sidual frozen tissue for immunoﬂuorescence (IF) staining
for COL4A5 and COL4A2. In light of ﬁndings of prior
studies suggesting that patients with autosomal recessive
AS have worse prognosis than those with X-linked
AS,15,16 we excluded 3 males who had an expression
pattern consistent with autosomal AS from the outcome
analysis. The remaining 25 patients were the subject of
this study. Because most of our patients did not undergo
genetic testing and because GBM lamellation similar to
what is seen in AS has been described in severe podo-
cytopathies including familial focal segmental glomer-
ulosclerosis due to non-COL4 gene mutations,17 we
excluded 7 patients with typical electron microscopy
(EM) ﬁndings of AS but without hearing loss or family
history of hematuria (including 6 with preserved
COL4A5 staining and 1 with loss of COL4A5 staining).
All renal biopsies were processed according to
standard techniques for light microscopy, IF, and EM.
For light microscopy, all cases were stained with
hematoxylin and eosin, periodic acid-Schiff, Masson’s
trichrome, and Jones methenamine silver. IF was per-
formed on 3- to 4-mm cryostat sections using polyclonal
ﬂuorescein isothiocyanate (FITC)-conjugated antibodies
to IgG, IgM, IgA, C3, C1q, kappa, lambda, ﬁbrinogen,
and albumin (Dako Corporation, Carpinteria, CA). EM
was performed on all cases. The median number of
glomeruli studied ultrastructurally was 2 (range, 1–5).45
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conjugated and Texas-red conjugated rat monoclonal
antibodies against COL4A5 (clones H53 and B51) and
COL4A2 (clone H25), respectively, as detailed in
Table 1. This mixture of monoclonal antibodies is
produced by Shigei Medical Research Institute
(Okayama, Japan) and is commercially available. The
H53 is speciﬁc to the IDVEF sequence at positions of
251–255 of COL4A5, B51 to the NC1 domain of
COL4A5, and H25 to the EAIQP sequence at positions
of 675–679 of COL4A2.18,19 Patients showing loss of
GBM, BC, and distal TBM positivity for COL4A5 were
classiﬁed as group 1, whereas patients with intact GBM,
BC, and distal TBM positivity for COL4A5 were clas-
siﬁed as group 2 (Figure 1). The COL4A5 and COL4A2
IF slides were reviewed by 2 renal pathologists (MEF
and SHN), who were blinded to EM ﬁndings. The re-
sults were recorded as positive versus negative staining
of GBM, BC, and distal TBM for COL4A5 and COL4A2.
There was 100% concordance rate between the 2 pa-
thologists. When positive, GBM staining was bright
(2þ or 3þ, scale 0–3þ), whereas BC and distal TBM
staining ranged from 1 to 3þ. Demographic informa-
tion, presenting renal clinical and laboratory ﬁndings,
and follow-up were obtained from patients’ medical
records and through conversations with the treating
nephrologists. The age at detection of overt proteinuria
(deﬁned as 24-hour urine protein collection of >300
mg/day or protein-to-creatinine ratio > 300 mg/g
creatinine) and the age at detection of stage 2 chronic
kidney disease (CKD) or worse (i.e., estimated glomer-
ular ﬁltration rate < 90 ml/min per 1.73 m2) were
recorded. Clinical patient characteristics at the time of
biopsy were also collected. Quantiﬁcation of protein-
uria was performed by 24-hour collection or by spot
urine protein-to-creatinine ratio when 24-hour urine
collection was not performed. Estimated glomerular
ﬁltration rate for children (#18 years) was calculated
by the revised Schwartz equation20 and for adults by
the Chronic Kidney Disease Epidemiology Collaboration
equation21 and expressed as ml/min per 1.73 m2.Table 1. Procedure for immunoﬂuorescence staining for COL4A5
and COL4A2
1. Cut a 4-mm section from the frozen tissue onto a charged slide.
2. Place the slide in Dako Wash buffer (Dako, catalog # K8007) for $2 min.
3. Incubate with the prediluted mixture of FITC-conjugated and Texas-red conjugated rat
monoclonal antibodies against COL4A5 (clones H53 and B51) and COL4A2 (clone
H25) (Cosmo Bio USA, catalog # SGE-CFT45325) for 30 min at room temperature.
4. Place the slide in Dako wash buffer for $2 min.
5. Replace Dako wash buffer with distilled water to rinse for $2 min.
6. Mount in Vector-Hard-Set Mounting Medium (Vector, catalog # H-1400).
7. Examine the slide under a dark ﬁeld ultraviolet (IF) microscope using a Texas Red/FITC
combination ﬁlter and an FITC ﬁlter alone.
COL4A2, collagen type IV alpha 2; COL4A5, collagen type IV alpha 5; FITC, ﬂuorescein
isothiocyanate.
46The severity of GBM ultrastructural alterations was
graded as class 1: <25% of the total glomerular capil-
lary surface area showing GBM basket weave change,
lamellation and/or scalloping (with or without thinning
of other loops), class 2: 25% to 75% of the total
glomerular capillary surface area showing these ﬁnd-
ings, and class 3: >75% of the total glomerular capil-
lary surface area showing these ﬁndings. The degree of
podocyte foot process effacement was graded as
0 (none), 1% to 25% of the total glomerular capillary
surface area showing effacement (mild), 26% to 50%
(moderate), or >50% (severe). TA/IF were graded on a
semiquantitative scale based on an estimate of the
percentage of renal cortex affected and recorded as
follows: 0 (none), 1% to 25% (mild), 26% to 50%
(moderate), or >50% (severe). The histologic assess-
ments including the EM ﬁndings were scored by 2
renal pathologists (SMS and SHN), who were blinded to
the diagnosis and COL4A5 IF staining results. For
scoring the EM class, there was concordance in 21 cases
and discordance in 4 cases (class 2 vs. 1 in 3 cases and
class 3 vs. 2 in 1 case). A consensus score was used in
these 4 cases. For assessing the percentage of total
peripheral capillary surface area with podocyte foot
process effacement, there was concordance in 23 cases
and discordance in 2 cases. A consensus score was used
in these 2 cases.
Statistical analyses were performed using SPSS for
Windows, version 17.0 (SPSS, Chicago, IL) and StatXact
for Windows, version 11.0 (Cytel Software Corporation,
Cambridge, MA). Continuous variables are reported
as the mean  SEM. Analyses were performed by
nonparametric exact statistical methods using the
Wilcoxon rank-sum test, the Kruskal-Wallis test, the
Jonckheere-Terpstra test, and the Fisher exact test, as
appropriate for variable type. Survival estimates (end-
points, overt proteinuria, stage 2 CKD or worse) were
computed by the method of Kaplan and Meier. Multi-
variate survival analyses were performed using the Cox
proportional hazards model (Cox regression). Statistical
signiﬁcance was assumed at P < 0.05. P values between
0.05 and 0.10 were considered to be of borderline sig-
niﬁcance. The study was approved by the Mayo Clinic
Institutional Review Board.
RESULTS
Expression Patterns of COL4A5 Staining
All of the 25 cases studied showed normal diffuse
positive staining of GBM, BC, and TBM for COL4A2. In
10 cases (40%) (group 1), there was loss of distal TBM
staining for COL4A5. Of these 10 cases, 2 showed
segmental loss of GBM staining for COL4A5 (mosaic
pattern), 7 showed global loss of GBM staining for
COL4A5, and 1 did not have glomeruli left in the frozenKidney International Reports (2017) 2, 44–52
Figure 1. COL4A5 expression patterns. (a,b) Images (same microscopic ﬁeld) from a patient in group 2 showing intact GBM, BC, and distal TBM
staining for COL4A5. (c,d) Images (same microscopic ﬁeld) from a patient in group 1 showing complete loss of staining of GBM, BC, and distal
TBM for COL4A5, consistent with X-linked Alport syndrome. (e,f) Images (same microscopic ﬁeld) showing complete loss of staining of GBM for
COL4A5 with intact staining of BC and distal TBM, consistent with autosomal Alport syndrome. Images (a), (c), and (e) were visualized under the
FITC immunoﬂuorescence ﬁlter, whereas images (b), (d), and (f) were visualized under the Texas Red/FITC combination immunoﬂuorescence
ﬁlter. Immunoﬂuorescence was performed using a mixture of FITC-conjugated and Texas-red conjugated rat monoclonal antibodies against
COL4A5 and COL4A2, respectively. All cases showed the normal diffuse staining of GBM, BC, and TBM for COL4A2 (red color in b, d, and f).
(Original magniﬁcation 200 for a–d and 100 for e and f.) BC, Bowman’s capsule; COL4A2, collagen type IV alpha 2; COL4A5, collagen type IV
alpha 5; FITC, ﬂuorescein isothiocyanate; GBM, glomerular basement membrane; TBM, tubular basement membrane.
Table 2. Statistically signiﬁcant pathologic differences between
patients with (group 1) or without (group 2) loss of staining for
COL4A5
Group 1 Group 2 P value
No. of cases 10 15
% global glomerulosclerosis 5.6  8.1 19.5  12.9 0.003
$ mild arteriosclerosis 2 (20%) 11 (73%) 0.01
EM class 0.01
1 0 7 (47%)
2 2 (20%) 3 (20%)
3 8 (80%) 5 (33%)
Data are expressed in mean  SD or number (percentage) of cases.
COL4A5, collagen type IV alpha 5; EM, electron microscopy.
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intact GBM, distal TBM, and BC staining for COL4A5
(Figure 1).
Pathologic Findings
The mean number of glomeruli sampled for light mi-
croscopy and the percentage of globally sclerotic
glomeruli for the entire cohort were 16 (range, 1–69)
and 14% (range, 0%–50%), respectively. Segmental
glomerulosclerosis was present in 36% of cases and
interstitial foam cells in 36% of cases. The degree of
TA/IF was none in 40%, mild in 44%, moderate in 8%,
and marked in 8%. The EM class was 1 in 28% of
cases, 2 in 20%, and 3 in 52%. Table 2 shows the
statistically signiﬁcant pathologic differences between
group 1 and group 2. Compared with group 2, group 1
had a lower percentage of global glomerulosclerosis
and lower degree of arteriosclerosis, likely reﬂecting
their younger age at biopsy (see later). Group 1 had
more prominent ultrastructural GBM abnormalities
(mean EM class 2.8 vs. 1.9, P ¼ 0.01) (Figure 2a–d).
None of the patients in group 1 had class 1 ultra-
structural ﬁndings (vs. 47% of patients in group 2,
P ¼ 0.02). There were no statistical differences between
the 2 groups with regard to the presence of segmentalKidney International Reports (2017) 2, 44–52sclerosis lesions, presence of interstitial foam cells,
degree of TA/IF, or degree of podocyte foot process
effacement (data not shown). One patient in group 2
had concurrent mild IgA nephropathy. Another patient
in group 2 who had ESRD at biopsy (performed at the
age of 34 years) showed concurrent chronic interstitial
nephritis with marked TA/IF.
Clinical Findings and Outcome
The cohort consisted of 25 males; 19 (76%) were
white, 3 (12%) Hispanic, 2 (8%) Asian, and 1 (4%) was
African American. The study included 3 brothers (all47
Figure 2. Electron microscopic ﬁndings. (a,b) Images from a 7-year-old boy with a family history of hematuria in his mother and grandmother.
Electron microscopy shows global thickening, basket weave splitting, and scalloping of the GBM (4800 for a and 13,000 for b). In this case,
there was complete loss of GBM, BC, and distal TBM staining for COL4A5. (c,d) Images from a 14-year-old boy with hearing loss and a family
history of Alport syndrome in his sister and grandmother. Electron microscopy showed mostly diffuse thinning of the GBM (c, 5800), but rare
GBM segments showed lamellation (d, 59,000). In this case, there was intact GBM, BC, and distal TBM staining for COL4A5. (e,f) Images from a
25-year-old man with a family history signiﬁcant for proteinuria and hematuria in his mother and end-stage renal disease in his grandmother.
Electron microscopy showed global thickening, basket weave splitting, and scalloping of the GBM (2900 for e and 11,000 for f). In this case,
there was intact GBM, BC, and distal TBM staining for COL4A5. BC, Bowman’s capsule; COL4A5, collagen type IV alpha 5; GBM, glomerular
basement membrane; TBM, tubular basement membrane.
Table 3. Statistically signiﬁcant clinical differences between
patients with (group 1) or without (group 2) loss of staining for
COL4A5
Group 1 Group 2 P value
No. of patients 10 15
Age at Bx 14.4  7.0 38.7  15.0 <0.001
Age at detection of overt proteinuria 12.4  6.7 30.8  16.1 <0.001
Age at detection of stage 2 CKD or worse 15.6  6.3 37.3  13.2 <0.001
White race 4 (40%) 15 (100%) 0.001
Serum creatinine at Bx in mg/dl 0.9  0.7 2.0  2.5 0.007
eGFR at Bx 99.4  34.5 67.1  32.7 0.03
Macroscopic hematuria 5 (50%) 2 (13%) 0.075
Data are expressed in mean  SD or number (percentage) of cases.
Bx, renal biopsy; CKD, chronic kidney disease; COL4A5, collagen type IV alpha 5; eGFR,
estimated glomerular ﬁltration rate.
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lated. All patients had a family history of hematuria
(with or without renal insufﬁciency) (present in 80%)
and/or hearing loss (present in 60%). At the time of
renal biopsy, 9 (36%) patients were children and 16
(64%) were adults, with a mean age of 29  17 years
(range, 7–67 years), a mean serum creatinine of 1.6 
2.1 mg/dl, a mean estimated glomerular ﬁltration rate of
80  36.5 ml/min per 1.73 m2, a mean 24-hour urine
protein of 2.0 1.9 g, and a mean serum albumin of 3.8
 0.5 g/dl. At biopsy, 96% of the patients had
microscopic hematuria, 36% hypertension, 83% overt
proteinuria, and 56% stage 2 CKD or worse; none had
full nephrotic syndrome. Table 3 shows the statistically
signiﬁcant clinical differences between patients in
group 1 and group 2. Patients in group 1 were younger
at biopsy and less likely to be white, and had a higher
estimated glomerular ﬁltration rate and lower serum
creatinine at biopsy likely reﬂecting younger age at
biopsy. Degree of proteinuria at biopsy, presence of
hypertension, level of serum albumin at biopsy, pres-
ence of family history, and presence of hearing loss48were not statistically different between the 2 groups.
Macroscopic hematuria tended to be more common in
group 1 (P ¼ 0.08). Post kidney biopsy follow-up was
available in 72% of patients (mean 35 months [31
months for group 1 and 38 months for group 2], range
7–102 months). During the follow-up period, 2 patients
(in group 2) developed ESRD at ages 34 and 47,
respectively.Kidney International Reports (2017) 2, 44–52
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Figure 3. Progression to overt proteinuria. COL4A5, collagen type IV alpha 5.
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1 patients developed overt proteinuria and stage 2 CKD
or worse at a younger age (P < 0.001 for both)
(Table 3). By Kaplan-Meier survival analysis and
Cox regression analysis, loss of staining for COL4A5
predicted earlier progression to overt proteinuria
(P < 0.001, median age 10 years [95% conﬁdence
interval (CI), 5.1–14.6] vs. 31 years [9.4–52.6]) and to
stage 2 CKD or worse (P < 0.001, median age 18 years
[95% CI, 14.7–21.3] vs. 40 years [26.4–54.0]) (Figures 3
and 4). There were not enough endpoints to calculate
for progression to ESRD. The presence of EM class 2 or
3 ﬁndings (vs. class 1) also predicted earlier progression
to overt proteinuria (P < 0.003, median age 18 years
[95% CI, 9.3–26.7] vs. 58 years [26.9–89.1]) and to stage
2 CKD or worse (P < 0.007, median age 29 years [95%
CI, 14–44] vs. 47 years [CI, 25.4–68.6]) (Figures 5 and 6).0
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Figure 4. Progression to CKD2 or worse. CKD2, stage 2 chronic kidney di
Kidney International Reports (2017) 2, 44–52In multivariate Cox regression analysis for all variables,
independent predictors of progression to overt pro-
teinuria were loss of staining for COL4A5 and % global
glomerulosclerosis; the only independent predictor for
progression to stage 2 CKD or worse was loss of staining
for COL4A5 (Table 4).
DISCUSSION
This is the ﬁrst study on AS to include mostly adults at
diagnosis. We have shown that loss of staining for
COL4A5 has prognostic value as it correlates with
earlier onset of proteinuria and stage 2 CKD, likely
reﬂecting the presence of large genetic defects and
hence major COL4 network alterations in these pa-
tients. Two previous studies addressing mostly chil-
dren with X-linked AS have found correlation between
loss of staining and earlier onset of proteinuria and35 40 45 50 55 60
(+) COL4A5 staining
(-) COL4A5 staining
P < 0.001
sease; COL4A5, collagen type IV alpha 5.
49
010
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30 35 40 45 50 55
P
E
R
C
E
N
T
Age (years)
EM class 1
EM class 2
EM class 3
P = 0.002
Figure 5. Progression of overt proteinuria according to EM class. EM, electron microscopy.
CLINICAL RESEARCH SM Said et al.: Signiﬁcance of Loss of Staining for COL4A5 in Alport SyndromeESRD.12,13 It has been shown in males with X-linked AS
that truncating mutations (nonsense, insertion, dele-
tion, splice site) in the COL4A5 gene typically lead to
loss of GBM staining for COL4A5, whereas missense
mutations can be associated with loss or intact
staining.12,22 Based on the above data, staining for
COL4A5 is recommended in the practice of renal pa-
thology in patients with a histologic diagnosis of AS.
The staining technique that we use in our laboratory
(detailed in Table 1) and that is used in several other
diagnostic renal pathology laboratories (such as Arkana
Laboratories and the Immunopathology Laboratory of
University of Minnesota) and in several prior
studies12,18,22 is simple, quick, and inexpensive as it is
a direct IF method involving incubating a single frozen
tissue section with a commercially available prediluted
mixture of FITC-conjugated COL4A5 and Texas-red0
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Figure 6. Progression to CKD2 or worse according to EM class. CKD2, st
50conjugated COL4A2 antibodies. It does however
require the addition of a Texas Red/FITC combination
ﬁlter to the routine IF microscope. The combination
ﬁlter is particularly useful to diagnose cases with
mosaic loss of COL4A5 staining, seen sometimes in fe-
males; in these cases, GBM segments negative for the
FITC-conjugated COL4A5 antibody appear red as they
retain their normal COL4A2 positivity.
The frequencies of X-linked, autosomal recessive,
and autosomal dominant AS were previously estimated
to be 80% to 85%, 15%, and 1% to 5%, respec-
tively.23,24 However, recent studies using next-
generation sequencing for mutation screening of
COL4A5, COL4A4, and COL4A3 have identiﬁed a
higher frequency of autosomal AS, particularly the
autosomal dominant type that accounted for 19% to
30% of cases.25,26 In our experience with 17 patients35 40 45 50 55 60
EM class 1
EM class 2
EM class 3
P = 0.02
age 2 chronic kidney disease; EM, electron microscopy.
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Table 4. Multivariate Cox regression analysis
HR 95% CI P value
Progression to overt proteinuria
(–) versus (þ) COL4A5 staining 10.17 2.43–42.49 0.001
% global glomerulosclerosis 0.93 0.87–0.99 0.017
Progression to stage 2 CKD or worse
(–) versus (þ) COL4A5 staining 11.35 2.66–48.53 0.001
CI, conﬁdence interval; CKD, chronic kidney disease; COL4A5, collagen type IV alpha 5;
HR, hazard ratio.
SM Said et al.: Signiﬁcance of Loss of Staining for COL4A5 in Alport Syndrome CLINICAL RESEARCHwith AS with loss of COL4A5 staining (including males
and females), 11 (65%) showed an expression pattern
consistent with X-linked disease whereas 6 (35%)
showed an expression pattern consistent with auto-
somal disease (example of the latter is shown in
Figure 1e and f), which is another reason for perform-
ing COL4A5 staining in patients suspected to have AS,
particularly those who cannot afford or are unwilling
to undergo genetic testing. Even in patients with
conﬁrmed mutations in COL4A5, COL4A4, or COL4A3,
COL4A5 expression evaluation is still warranted as
some mutations may not be pathogenic and, as was
shown recently, heterozygous mutations in COL4A4 or
COL4A3 are present in 10% of patients with familial
focal segmental glomerulosclerosis (with EM ﬁndings
inconsistent with classic AS).27
Previous studies on AS that included 90% to 100%
children have found loss of staining for COL4A5 in
over two-thirds of patients.12–14,24 In contrast, in our
renal biopsy-based series in which 64% of patients
were adults at biopsy, only 40% of patients showed
loss of staining for COL4A5, including 89% (8 of 9) of
children and 13% (2 of 16) of adults. The high per-
centage of adults in our cohort reﬂects our general
renal biopsy practice in which the vast majority of
biopsies are from adults, with pediatric biopsies ac-
counting for only 2% of our native renal biopsies.
Similar to our experience, only 38% (6 of 16) of the
patients tested by Markowitz et al.7 who were mostly
adults at biopsy had loss of GBM staining for COL4A5.
As patients with loss of staining for COL4A5 typically
develop proteinuria and stage 2 CKD at an early age,
they tend to undergo diagnostic renal biopsy during
childhood. Hence, only a small minority of patients
with AS diagnosed in adulthood are expected to have
loss of staining for COL4A5, a point that has not been
addressed in the literature.
In this study, we found a correlation between the
loss of staining for COL4A5 and the severity of ultra-
structural GBM alterations. None of the cases that
showed mild ultrastructural alterations (i.e., focal GBM
basket weave change, with or without thinning of
other loops) showed loss of staining for COL4A5. As
illustrated in Figure 2e and f, even cases with strikingKidney International Reports (2017) 2, 44–52global GBM basket weave change may show intact
staining for COL4A5, and therefore EM is more sensi-
tive than immunostaining for COL4A5 to diagnose AS.
Because we studied only males who were mostly
diagnosed with AS in adulthood, caution is warranted
in extrapolating our results to children and females.
This work has some noteworthy limitations. (1) It is
a retrospective study with a small sample size. (2) Only
2 (8%) patients developed ESRD. This is likely in part
due to the lack of long-term follow-up. Because most of
our patients were diagnosed in adulthood and had
intact staining for COL4A5, the low incidence of ESRD
may also be a reﬂection of milder genetic defects in
these patients (i.e., selection bias). (3) Genotype-
phenotype correlations were not possible as the ma-
jority of patients included in this study did not
undergo genetic testing. Several previous studies have
addressed the relationship between COL4A5 mutations
and the pattern of COL4A5 staining in X-linked
AS.3,12,13,22 With the recent improved mutational
screening through next-generation sequencing, future
studies evaluating the relationship between COL4A4
and COL4A3 mutations and the pattern of COL4A5
staining in autosomal AS will likely become possible.
In this study, we show that loss of staining for
COL4A5 correlates with more severe GBM ultrastruc-
tural alterations, a younger age at diagnosis, and earlier
progression to overt proteinuria and stage CKD2 or
worse, likely reﬂecting larger genetic defects in these
patients; hence, staining for COL4A5 provides impor-
tant prognostic information in patients with AS.
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